In mouse models of NASH-related HCC, dipeptidyl peptidase-4 inhibitor (DPP4i) inhibits the p62/Keap1/Nrf2 pathway to downregulate the PPP pathway, thereby halting the progression of NASH-related HCC (161). Here, KEAP1 is linked to hepatocellular carcinoma.